Voyager Therapeutics price to sales ratio VYGR

Market value divided by revenue over the last twelve months, since 2016.

Today, Oct 23, 2026: 3.1×
10-year median: 7.0×
Against its 10-year history: 19th; percentile: 0 is its lowest day, 100 its highest
10-year range: 0.7× to 132×
Peer median: 2.0×

Voyager Therapeutics' price to sales ratio is 3.1× as of Oct 23, 2026.

That is below its ten-year median of 7.0×, lower than on 81% of days in the last ten years.

Over that time it ranged from 0.7× in Jul 2021 to 132× in Mar 2018.

The median for 10 healthcare stocks of a similar size is 2.0×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	3.1×	3.1×	7.3×
2025	7.2×	2.1×	7.8×
2024	n/m a value too high to mean anything
2023	4.9×	3.8×	5.9×
2022	3.3×	3.0×	9.6×
2021	6.5×	0.7×	9.1×
2020	1.4×	1.4×	7.2×
2019	7.0×	6.5×	96.4×
2018	24.8×	23.8×	132×
2017	72.7×	17.4×	74.8×
2016	20.3×	13.5×	23.2×

Against its peers

Companies in Healthcare nearest Voyager Therapeutics' size, closest first, today.

Company	Price to sales ratio
VYGRVoyager Therapeutics	3.1×
KEQUKewaunee Scientific	0.3×
ICCCImmucell	3.0×
LFVNLifevantage	0.4×
SPROSpero Therapeutics	1.4×
PDEXPro DEX	2.6×
APTAlpha Pro Tech	0.9×
PLXProtalix BioTherapeutics	2.5×
NATRNatures Sunshine Products	0.4×
ELMDElectromed	3.0×
UTMDUtah Medical Products	6.5×
Peer median	2.0×

Where Voyager Therapeutics ranks

#14of 63Biotech stocks with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Voyager Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.